Mirum Pharmaceuticals, Inc. filed a Form 8-K on September 8, 2026, disclosing the appointment of Rob Myers, M.D., as Chief Medical Officer and the planned departure of Joanne Quan, M.D., from that role, effective September 2, 2026.
Key Highlights
- New CMO appointed: Rob Myers, M.D., was appointed by the Board of Directors on September 2, 2026, to serve as Chief Medical Officer, with employment expected to begin September 21, 2026.
- Outgoing CMO: Joanne Quan, M.D., ceased serving as Chief Medical Officer effective September 2, 2026, with her termination of employment expected on October 19, 2026.
- Severance benefits: Dr. Quan is expected to receive severance benefits under the Company's Amended and Restated Severance Benefit Plan, subject to its terms and conditions.
- Stock option extension: The Compensation Committee approved an extension of the post-termination exercise period for Dr. Quan's vested and outstanding stock options to 12 months after the Separation Date.
- Bonus payment: The Compensation Committee approved payment of Dr. Quan's 2026 annual target bonus at the 100% achievement level, payable on the Separation Date, contingent on customary conditions.
- Separation classification: Dr. Quan's departure "is expected to qualify as an involuntary termination" under the Severance Plan, according to the filing.
Mirum Pharmaceuticals CMO Transition: Appointment, Separation Terms, and Compensation Details
According to the filing, Mirum Pharmaceuticals' Board of Directors acted on September 2, 2026, to appoint Rob Myers, M.D., as the Company's next Chief Medical Officer. Dr. Myers is expected to begin employment on September 21, 2026, at which point his appointment becomes effective. The company is listed on the Nasdaq Global Market under the ticker NASDAQ:MIRM.
The filing discloses that Joanne Quan, M.D., stepped down from the Chief Medical Officer role on September 2, 2026, with her full separation from the company expected on October 19, 2026, referred to in the filing as the "Separation Date." In connection with her departure, the company and Dr. Quan expect to enter into a Separation Agreement. The filing notes that the description provided "is only a summary of the terms thereof, does not purport to be complete," and that the final Separation Agreement is anticipated to be filed with a future quarterly or annual report.
The Compensation Committee approved two additional benefits for Dr. Quan, both contingent on her satisfying "certain customary conditions" in the final Separation Agreement: a 12-month extension of the post-termination exercise window for all vested and outstanding stock options held on the Separation Date, and payment of her full 2026 annual target bonus at the 100% achievement level. The filing notes the departure is expected to qualify as an involuntary termination under the Severance Plan. The filing also contains forward-looking statements, which the company identified as subject to risks and uncertainties and its standard cautionary language.
What Was Disclosed
Mirum Pharmaceuticals disclosed a CMO leadership change, with Rob Myers, M.D., set to replace Joanne Quan, M.D., along with separation-related compensation arrangements for Dr. Quan, including severance benefits, a stock option exercise extension, and a full 2026 target bonus payment.




Please wait processing your request...